PTC Therapeutics | PTCT - Current Assets


PTC Therapeutics reported $2.01B in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.08B 115.87M Sep/2025
Alnylam Pharmaceuticals USD 3.95B 309.11M Sep/2025
Amgen USD 27.88B 1.15B Sep/2025
Biogen USD 8.94B 968.9M Sep/2025
BioMarin Pharmaceutical USD 3.85B 49.21M Sep/2025
Cytokinetics USD 977.35M 90.81M Sep/2025
Daiichi Sankyo JPY 2.1T 218.5B Dec/2025
Gilead Sciences USD 18.84B 4.12B Sep/2025
Incyte USD 4.28B 634.19M Sep/2025
Ionis Pharmaceuticals USD 2.52B 58.16M Sep/2025
Ironwood Pharmaceuticals USD 273.84M 82.09M Sep/2025
Novartis USD 28.2B 2.26B Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
PTC Therapeutics USD 2.01B 265.07M Sep/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
Sarepta Therapeutics USD 2.72B 65.32M Sep/2025
TG Therapeutics USD 599.76M 64.2M Sep/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Vertex Pharmaceuticals USD 10.57B 141.7M Sep/2025
Xencor USD 518.44M 5.29M Sep/2025